title: Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia.
abstract: OBJECTIVE
  To determine among a cohort of patients newly dispensed a prescription for a proton pump inhibitor (PPI) the extent of prior use of other less expensive agents such as antacids and H2-receptor antagonists as evidence of a 'stepped care' approach to peptic ulcer and oesophageal disease.
  
  
  METHODS
  A retrospective drug utilization study was conducted within the Pharmaceutical Benefits Scheme (PBS) claims database in Australia. A cohort of social security recipients, who received approval for PPI supply in the month of October 1996, had no prior PPI approval in the previous 18 months and went on to have the drug dispensed, was assembled. This group of 'new PPI starters' was then examined for supply of less expensive prescription medicines to treat peptic ulcer and oesophageal disease in the 12 months prior to obtaining their PPI approval.
  
  
  RESULTS
  In a cohort of 4554 defined new PPI users, 1205 (26.5%) showed no use of H2-receptor antagonists, antacids, cisapride, cytoprotectants or antiregurgitants in the 12 month period prior to commencing the PPI. The major reason for use given by prescribers for PBS supply was 'severe refractory ulcerating oesophagitis'.
  
  
  CONCLUSIONS
  Subsidized supply is currently restricted on cost-effectiveness grounds to refractory peptic ulcer disease or severe oesophageal disease. Despite this, utilization and epidemiological data suggest that there is widespread leakage of use outside these indications particularly to less severe forms of oesophageal disease. This patient tracking study has shown within the PBS database that around a quarter of the patients are treated directly with a PPI without being prescribed less expensive agents at least in the preceding 12 months.
authors.affiliation: Department of Health & Family Services, Canberra, Australia.
authors.forename: P
authors.initials: P
authors.lastname: McManus
authors.forename: J
authors.initials: J
authors.lastname: Marley
authors.forename: D J
authors.initials: DJ
authors.lastname: Birkett
authors.forename: J
authors.initials: J
authors.lastname: Lindner
mesh_terms: D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001315:Australia; D015331:Cohort Studies; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization; D004935:Esophageal Diseases / Q000188:drug therapy; D019983:Guideline Adherence; D006801:Humans; D009313:National Health Programs; D010437:Peptic Ulcer / Q000188:drug therapy; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D017494:Proton Pumps